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Objective?The Korean Medication Algorithm for the Treatment of Schizophrenia was developed by the extensive 
review and questionnaires. To evaluate the impact of a history of antipsychotic treatments on clinical response 
and algorithm application, using the data derived from the feasibility study of the Medication Algorithm for patients 















to 4 months are presented. Measures of changes included clinical symptoms, functioning, and side effects. 
Comparison was done between patients with and without a history of antipsychotic treatments. Results?100 
individuals ?with a history?71?without a history?29? were analyzed for the comparison. Most of subjects without 
a history of antipsychotic treatments were administered on risperidone in the initial treatment. When compared 
with the subjects with a treatment history, the subjects without a history showed better treatment effects on clinical 
symptoms at the first evaluation. At 4-month, there were similar effects between the two groups except negative 
symptoms, in which the group with a history showed significantly more improvement than without a history. There 
were no significant differences in assessment of subjective opinion and well-being to drugs and quality of life, 
and objective evaluation of drug side effects. Among the subjects with a history, the ones starting with stage 1 
showed higher positive symptoms, anxiety scores, and briefer duration of antipsychotic exposure than the ones 
starting with stage 2 or more advanced. Conclusion?This study suggests that despite some limitation, an antip-
sychotic treatment history may have an impact on application of medication algorithm and these data will be helpful 
for revision of the Medication Algorithm for the Treatment of Schizophrenia. (Korean J Psychopharmacol 2006; 
17(2):162-173) 
 



































































대상 및 방법 
?
1. 연구대상 
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Table 1. Characteristics of subjects in this report 
  Subjects without a history of antipsychotic treatment ?N=29? 
Subjects with a history of  
antipsychotic treatment ?N=71? 
Age ?year? 31.3?8.7 32.2?8.8 
Male, N ?%? 13 ?44.8? 37 ?52.1? 
Education ?year? 14.0?2.6 13.2?2.6 
Age at first psychiatric treatment - 26.7?7.6 
Diagnostic subtypes, N ?%?     
Paranoid Schizophrenia 24 ?82.8? 49 ?69.0? 
Undifferentiated Schizophrenia 04 ?13.8? 20 ?28.2? 
Other subtypes or disorder 01 ?03.4?a 02 ?02.8?b 
Treatment hospital, N ?%?*     
General hospital 27 ?93.1? 54 ?76.1? 
Psychiatric hospital 02 ?06.9? 17 ?23.9? 
*??2=3.888, df=1, p?0.05, a?schizophreniform disorder, b?catatonic and residual subtypes 
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Table 2. Use of antipsychotics and stages of beginning 
 Subjects without a history of antipsychotic treatment ?N?29? 
Subjects with a history of antipsychotic 
treatment ?N?71? 
Use of Antipsychotics  N ?%? Max. dose ?mg? N ?%? Max. dose ?mg? 
Risperidone 22 ?75.9? 005.1?001.9 41 ?57.7? 005.6?001.6 
Olanzapine 03 ?10.3? 020.8?005.2 11 ?15.5? 017.7?004.7 
Quetiapine 03 ?10.3? 500.0?264.6 09 ?12.7? 666.7?167.7 
Clozapine - - 06 ?08.5? 439.6?215.1 
Other atypicals - - 01 ?01.4? - 
Typicals 1 ?3.1? - 03 ?04.2? - 
Stage of beginning, N ?%?*    
Stage 1 28 ?96.6? 54 ?76.1? 
?Stage 2 01 ?03.4? 17 ?23.9? 
Stage 2 0 7 
Stage 3 1 4 
Stage 4 0 0 
Stage 5 0 6 
*??2=5.860, df=1, p?0.05 






































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Change of Brief Symptom Rating Scale mean
scores in patients with or without a history of antipsy-
chotic treatment. All are statistically significant in paired
t-tests between baseline and first evaluation or 4 months 
in each group with or without an antipsychotic treat-
ment history (p<0.001). BPSS?Brief Positive Symptom 
Scale, BNSS?Brief Negative Symptom Scale. 
Baseline First evaluation 4 months Baseline  
? Without antipsychotic history 
N=27 N=27 N=19 N=19 
? With antipsychotic history 





























































































Table 4. Satisfaction on antipsychotics and quality of life in patients with or without a history of antipsychotic treatment 
Subjects without a history of antipsychotic 
treatment  
Subjects with a history of antipsychotic 
treatment  
Change in scores from baseline Change in scores from baseline  Baseline 
score First evaluation 4 months 
Baseline 
score First evaluation 4 months 
Drug attitude inventory       
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WHO QOL  ?   ?  


















































SWN?Subjective Well-being on Neuroleptics Scale, WHO QOL?World Health Organization Quality of Life Scale.  
*?p?0.05 between subjects with and without a history of antipsychotic treatment in Mann-Whitney U-test 














5. 과거 약물 사용군에서 1단계와 2단계 이상으로 등록된 
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Table 5. Side effects induced by antipsychotics in patients with or without a history of antipsychotic treatment 
Subjects without a history of  
antipsychotic treatment  
Subjects with a history of  
antipsychotic treatment   
Baseline First 
evaluation 
4 months Baseline First evaluation 4 months 
LUNSERS             
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LUNSERS?Liverpool University Neuroleptics Side Effect Rating Scale, UKU?UKU side effect rating scale. *?p?0.05 
between subjects with and without a history of antipsychotic treatment in independent t-test. ??t=-1.94, df=34, 
p=0.061 























Table 6. Clinical characteristics at registration according to stages of beginning in patients with a history of antipsy-
chotic treatment 
  Subjects beginning at stage 1 Subjects beginning at stage 2 or more 
Age at registration ?years old? 32.5?8.6 ?N?54? 30.8?9.5 ?N?17? 
Duration of antipsychotic treatments, N ?%?*     
< 6 months 19 ?41.3? 1 ?10.0? 
6-12 months 07 ?15.2? 0 ?00.0? 
12-24 months 09 ?19.6? 4 ?40.0? 
> 24 months 11 ?23.9? 5 ?50.0? 
Response to antipsychotic treatments, N ?%?     
Complete response  08 ?16.0? 01 ?07.1? 
Partial response 40 ?80.0? 11 ?78.6? 
No response 02 ?04.0? 02 ?14.3? 
No. of previous admission 03.2?3.0 ?N?40? 03.4?3.0 ?N?15? 
Age at first admission ?years?* 27.6?7.7 ?N?39? 22.7?6.5 ?N?15? 
Age at first psychiatric treatment ?years? 26.4?7.0 ?N?52? 24.1?8.1 ?N?16? 
Global severity of symptoms and side effectsa   
Positive symptoms 05.5?2.2 ?N?52? 04.4?1.8 ?N?17? 
Negative symptoms 03.5?3.0 ?N?51? 03.8?1.3 ?N?17? 
Cognitive impairments 03.3?1.5 ?N?51? 02.9?1.0 ?N?17? 
Agitation/irritablity 03.7?1.6 ?N?53? 03.0?1.4 ?N?15? 
Depression 02.2?1.2 ?N?53? 01.8?1.1 ?N?15? 
Insomnia 03.2?1.5 ?N?53? 02.7?1.2 ?N?15? 
Obsessive-compulsive symptoms 01.7?1.1 ?N?53? 01.5?1.0 ?N?15? 
Anxiety* 03.4?1.3 ?N?53? 02.6?1.2 ?N?15? 
Extrapyramidal symptoms 01.1?0.5 ?N?53? 01.5?0.8 ?N?15? 
Akathisia 01.2?0.7 ?N?53? 01.4?0.7 ?N?15? 
Tardive dyskinesia 01.2?0.8 ?N?53? 01.3?1.3 ?N?15? 
Autonomic nervous system effects  01.1?0.3 ?N?53? 01.3?1.0 ?N?15? 
Weight gain 01.2?0.9 ?N?53? 01.2?0.8 ?N?15? 
Scores of psychotic symptom scales    
Brief Positive Symptom Scale* 18.7?4.1 ?N?51? 15.9?5.2 ?N?17? 
Brief Negative Symptom Scale  13.6?5.4 ?N?51? 14.4?5.5 ?N?17? 
Conceptual disorganization? 03.8?1.6 ?N?51? 03.1?1.0 ?N?17? 
Total score of the above scales 36.1?7.8 ?N?51? 33.4?8.6 ?N?17? 
*?p<0.05 and ??p=0.053 in ?2 or independent t-test. aSeverity?1=none, 2=minimal, 3=mild, 4=moderate, 5= 
moderate severe, 6=severe, 7=profound. 
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